Streetbeat News

Products Services

ALDX

Aldeyra Therapeutics reported positive top-line results from the Phase 2 clinical trial of orally administered ADX-629, showing a significant reduction in cough frequency compared to placebo. A Phase 2 trial for ADX-629 in moderate alcohol-associated hepatitis is expected to begin in H2 2023.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:07 am

ANF

GXO

GXO Logistics expands its partnership with Abercrombie & Fitch to the U.K., enabling the adult apparel brand to expand its e-commerce offering, increase service flexibility, and reduce inventory concentration.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:05 am

NKTX

Nkarta reports updated data from its Phase 1 study of NKX101, an allogeneic cell therapy candidate, to treat patients with relapsed or refractory acute myeloid leukemia. The therapy uses NK cells derived from healthy donors and targets NKG2D ligands on cancer cells.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:03 am

ACIU

AC Immune has secured FDA Fast Track designation for its anti-amyloid-beta active immunotherapy, ACI-24.060, aimed at treating Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 11:01 am

META

Meta Platforms Inc. (NASDAQ:META) has introduced a new suite of parental supervision tools for Facebook Messenger, allowing parents and guardians to monitor their teen children's activity, including contacts, blocked users, and privacy settings. The tools are currently available in the US, UK, and Canada, with plans to expand to other markets.

Portfolio Pulse from Rounak Jain

June 27, 2023 | 10:50 am

META

Meta Platforms announced that small businesses using the WhatsApp Business App will soon be able to create ads that click to WhatsApp without a Facebook account. They will also have the option to send personalized texts to clients.

Portfolio Pulse from Charles Gross

June 27, 2023 | 10:49 am

PFE

The FDA has accepted Pfizer's Biologics License Application for Fidanacogene Elaparvovec, a treatment for adults with Hemophilia B. The FDA set a PDUFA goal date in Q2 of 2024. The European marketing authorization application has also been accepted and is under review by the EMA.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 10:47 am

BRTX

BioRestorative Therapies (BRTX) announced that no dose limiting toxicity (DLT) was observed in the safety run-in segment of their study.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 10:38 am

BRTX

BioRestorative Therapies' Data Monitoring Committee has allowed the company's Chronic Lumbar Disc Disease study to continue unchanged.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 10:37 am

EGAN

eGain has introduced a unique pilot program for generative AI, allowing businesses to test the AI and knowledge capabilities for two weeks in a production setting without any cost, commitment, or catch.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 10:34 am